Industrial Alliance Investment Management Inc. Has $2.78 Million Position in Natera, Inc. (NASDAQ:NTRA)

Industrial Alliance Investment Management Inc. lowered its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Get Rating) by 19.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,317 shares of the medical research company’s stock after selling 15,300 shares during the period. Industrial Alliance Investment Management Inc.’s holdings in Natera were worth $2,775,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC boosted its stake in shares of Natera by 12.9% in the 3rd quarter. Signaturefd LLC now owns 2,094 shares of the medical research company’s stock valued at $92,000 after purchasing an additional 240 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Natera by 1.2% in the 3rd quarter. Arizona State Retirement System now owns 24,864 shares of the medical research company’s stock valued at $1,090,000 after purchasing an additional 285 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Natera by 1.7% in the 3rd quarter. Amalgamated Bank now owns 19,301 shares of the medical research company’s stock valued at $846,000 after purchasing an additional 322 shares in the last quarter. Profund Advisors LLC boosted its stake in shares of Natera by 3.3% in the 3rd quarter. Profund Advisors LLC now owns 10,571 shares of the medical research company’s stock valued at $463,000 after purchasing an additional 337 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in shares of Natera by 0.8% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 43,299 shares of the medical research company’s stock valued at $1,897,000 after purchasing an additional 341 shares in the last quarter. Institutional investors and hedge funds own 93.81% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $58.29 on Friday. The stock has a market capitalization of $6.60 billion, a P/E ratio of -10.46 and a beta of 1.20. Natera, Inc. has a 1-year low of $27.35 and a 1-year high of $59.75. The company has a current ratio of 3.90, a quick ratio of 3.79 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average price of $46.72 and a two-hundred day moving average price of $44.22.

Natera (NASDAQ:NTRA – Get Rating) last announced its quarterly earnings data on Tuesday, February 28th. The medical research company reported ($1.37) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.03. The firm had revenue of $217.30 million during the quarter, compared to analysts’ expectations of $215.50 million. Natera had a negative return on equity of 106.67% and a negative net margin of 66.79%. The company’s quarterly revenue was up 25.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.48) EPS. Equities analysts predict that Natera, Inc. will post -4.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NTRA. Morgan Stanley boosted their target price on shares of Natera from $70.00 to $72.00 and gave the company an “overweight” rating in a research note on Thursday, March 2nd. Credit Suisse Group lifted their price target on Natera from $55.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, March 1st. StockNews.com initiated coverage on Natera in a report on Thursday. They issued a “sell” rating for the company. Piper Sandler lifted their price target on Natera from $70.00 to $80.00 in a report on Friday, February 17th. Finally, Raymond James lifted their price target on Natera from $58.00 to $68.00 and gave the company an “outperform” rating in a report on Friday, March 3rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $79.27.

Insiders Place Their Bets

In other news, CFO Michael Burkes Brophy sold 915 shares of the company’s stock in a transaction dated Wednesday, December 28th. The stock was sold at an average price of $39.84, for a total value of $36,453.60. Following the completion of the sale, the chief financial officer now directly owns 91,350 shares of the company’s stock, valued at approximately $3,639,384. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Michael Burkes Brophy sold 915 shares of the company’s stock in a transaction dated Wednesday, December 28th. The stock was sold at an average price of $39.84, for a total value of $36,453.60. Following the completion of the sale, the chief financial officer now directly owns 91,350 shares of the company’s stock, valued at approximately $3,639,384. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 1,660 shares of the company’s stock in a transaction dated Friday, December 23rd. The shares were sold at an average price of $42.30, for a total value of $70,218.00. Following the completion of the sale, the chief executive officer now directly owns 82,632 shares of the company’s stock, valued at $3,495,333.60. The disclosure for this sale can be found here. In the last three months, insiders sold 187,145 shares of company stock valued at $8,648,357. 10.27% of the stock is currently owned by insiders.

About Natera

(Get Rating)

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).